Navigation Links
Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing
Date:10/14/2008

MOUNTAIN VIEW, Calif., Oct. 14 /PRNewswire/ -- Based on its recent analysis of the bone healing market, Frost & Sullivan recognizes ISTO Technologies, Inc. with the 2008 North American Frost & Sullivan Award for Product Innovation for its novel InQu(R) Bone Graft Extender and Substitute scaffold. InQu represents the first commercial product launched by the company using its proprietary biomaterial-based platform technology.

Although spinal fusions and other orthopedic intervention methods are routinely used to eliminate back pain, surgeons are still unsure about the right choice in bone grafting materials. While autologous grafts have traditionally been considered the "gold standard" in treatment, the pain associated with harvesting autologous bone, along with an increase in operation and recovery times, and high rates of complications including donor site morbidity have made a case for alternative treatments.

"ISTO Technologies' InQu Bone Graft Extender and Substitute brings to the forefront the strengths and biological attributes of two reliable, safe, and effective biomaterials: Poly lactide-co-glycolide (PLGA) and hyaluronic acid (HyA)," explains Frost & Sullivan Research Analyst Pramodh Ishwarakrishnan. "The unique InQu scaffold creates a microenvironment that is both biocompatible and conducive to new bone formation."

These two major components of the scaffold have specific contributions to the overall healing process. PLGA, while giving the three-dimensional structure to InQu, also provides a reliable resorption rate at the site of implantation. HyA has been shown to play a critical role in tissue regeneration and repair, apart from promoting the migration, proliferation, and differentiation of osteogenic cells during the early stages of normal bone formation.

"The ideal combination of PLGA and HyA offers the advantages of superior cohesiveness, molding properties, handling characteristics and consistently predictable results," observes Ishwarakrishnan. "The HyA component may provide supplementary biological cues necessary for cells to grow and for the tissue to develop, thus making InQu a versatile scaffold, superior to any osteoconductive material in the market."

The InQu Bone Graft Extender offers several advantages over existing synthetic bone graft substitutes including its unique ability to support the normal process of endochondral bone formation. It also eliminates the potential risk of infection that is common with allograft transplants.

ISTO Technologies has a team of committed scientists and staff working towards delivering high-quality orthobiologic products to the medical community. InQu has already won clearance from Food and Drug Administration (FDA) as a bone graft extender and substitute. The company has several InQu- related patents pending and intends to develop additional applications for the biomaterial technology in the near future.

"The company's development pipeline includes NuQu(TM), a cell-based injectable formulation of juvenile chondrocytes for nucleus regeneration of the spinal disc," notes Ishwarakrishnan. "In addition to this, the company is in clinical trials with DeNovo(R) ET, its scaffold-free living cartilage graft based on its patented cell based technology platform, to repair and regenerate damaged knee cartilage."

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in new products and technologies within its industry. The recipient company has shown innovation by launching a broad line of emerging products and technologies.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About ISTO Technologies, Inc.

ISTO Technologies, Inc. is a privately-held orthobiologics company based in St. Louis, MO. The company is focused on developing breakthrough products designed to regenerate and restore damaged cartilage and bone for sports medicine injuries, trauma and spinal therapy indications. ISTO's discrete cell-based and biomaterial platforms encompass a number of technological breakthroughs that are poised to advance the practice of medicine by offering solutions for unmet and/or largely unsatisfied clinical needs in large orthopedic markets. ISTO's mix of clinical stage, development stage and marketed products includes DeNovo(R) ET, engineered cartilage to repair and restore joint function in the knee, NuQu(TM), a cell-based injectable formulation of juvenile chondrocytes for nucleus regeneration of the spinal disc and InQu(R), an osteobiologic bone graft substitute and extender. For more information about ISTO, visit http://www.istotech.com

Contact:

Scott Gill

(314) 995-6049

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.awards.frost.com.

Contact:

Jake Wengroff

210.247.3806

jake.wengroff@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award
2. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
3. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
4. Signalife Wins Second Frost & Sullivan Technology Award
5. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
6. Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
7. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
8. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
9. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... ... of fracture-specific plating options designed to address fractures of the distal tibia and ... , The Acumed Ankle Plating System 3 is composed of seven plate families ...
(Date:5/25/2016)... Bethesda, Md. (PRWEB) , ... May 25, 2016 ... ... a request for information (RFI) issued by the Office of the National Coordinator ... the patient experience, and determines if clinically relevant data were available when and ...
(Date:5/25/2016)... ... 25, 2016 , ... WEDI, the nation’s leading authority on the use of ... Stellar has been named by the WEDI Board of Directors as WEDI’s president and ... leader with more than 35 years of experience in healthcare, association management and organizational ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug designation ... company’s second orphan drug designation granted by the FDA. , Spinocerebellar ataxia ...
Breaking Biology Technology:
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
Breaking Biology News(10 mins):